Yanan Ren

No ORCID on file · 6 papers in corpus · active 2024-2025

Study types

  • other 3
  • article 2
  • preprint 1

Condition tags

  • endometriosis 6
other 2025
Association Between Remnant Cholesterol and Endometriosis Findings from NHANES 1999-2006
International journal of women's health ·doi:10.2147/IJWH.S568397

BACKGROUND: Endometriosis is a chronic gynecological disorder causing significant morbidity and health burden. Recent evidence suggests that lipid metabolism, particularly remnant cholesterol (RC), may be involved in its development. RC-the…

article 2025
Association Between Remnant Cholesterol and Endometriosis Findings from NHANES 1999–2006

Luyang Su,1,* Xiaona Wang,2,* Junqin Zhang,2,* Ren Xu,3,* Yanan Ren,2,* Shaoqing Wang4,* 1Physical Examination Center, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China; 2Department of Obstetr…

other 2025
Association between the C-reactive protein-triglyceride-glucose index and endometriosis: a cross-sectional study using data from the national health and nutrition examination survey, 1996-2006
BMC women's health ·doi:10.1186/s12905-024-03541-x

BACKGROUND: The C-reactive protein-triglyceride glucose index (CTI) is a promising new marker for evaluating the severity of inflammation. Endometriosis (EM) is a prevalent chronic inflammatory condition influenced by estrogen, primarily af…

article 2025
Association between urinary arsenic and the prevalence of endometriosis in women in the United States
Frontiers in public health ·doi:10.3389/fpubh.2025.1525986

BACKGROUND: Endometriosis affects up to 15% of women of reproductive age and can lead to various symptoms. More than 200 million people worldwide are at risk of higher than safe levels of arsenic exposure through drinking water. Studies inv…

preprint 2024
Associations between C-reactive protein-triglyceride glucose index and Endometriosis: the NHANES 1999-2006
·doi:10.21203/rs.3.rs-5181764/v1
other 2024
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
Frontiers in pharmacology ·doi:10.3389/fphar.2024.1491032

BACKGROUND: Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, l…